Crohn's DiseaseSymptoms, Doctors, Treatments, Advances & More
Crohn's Disease Overview
Learn About Crohn's Disease
Stephen Hanauer is a Gastroenterologist practicing medicine in Chicago, Illinois. Dr. Hanauer is rated as an Elite provider by MediFind in the treatment of Crohn's Disease. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Crohn's Disease, Viral Gastroenteritis, Ulcerative Colitis, Colonoscopy, and Endoscopy. Dr. Hanauer is board certified in American Board Of Internal Medicine - Gastroenterology (Certified). Dr. Hanauer is currently accepting new patients.
UChicago Medicine Northbrook
David Rubin is a Gastroenterologist and a Hepatologist practicing medicine in Northbrook, Illinois. Dr. Rubin is rated as an Elite provider by MediFind in the treatment of Crohn's Disease. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Ulcerative Colitis, Crohn's Disease, Viral Gastroenteritis, Ileostomy, and Endoscopy. Dr. Rubin is board certified in Practicing Since1994 and Gastroenterology. Dr. Rubin is currently accepting new patients.
Cleveland Clinic Main Campus
Benjamin Cohen is a Gastroenterologist practicing medicine in Cleveland, Ohio. Dr. Cohen is rated as an Elite provider by MediFind in the treatment of Crohn's Disease. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Crohn's Disease, Viral Gastroenteritis, Colitis, Ileostomy, and Colonoscopy. Dr. Cohen is board certified in American Board Of Internal Medicine, 2011. Dr. Cohen is currently accepting new patients.
Summary: Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group. The studies aim to evaluate the efficacy and safety of new treatments in adults with moderately to severely active ulcerative colitis or Crohn's disease and will last at least 6...
Summary: The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD). This study is part of the IIBD master protocol and will last approximately 62 weeks.


